Claimed effect · Survodutide

Does Survodutide help with liver disease?

B
Grade B — probable, not settled1 phase 2 RCT; phase 3 running · effect size: large
Short answerProbable, not settled. Human data exist (1 phase 2 RCT; phase 3 running) and mostly agree, showing a large effect — but too few, too small, or not yet peer-reviewed for a firm answer. Phase 2 in 293 patients: MASH improvement without worsening fibrosis in 83% at 4.8 mg versus 18% on placebo at 48 weeks; fibrosis improvement in 52% versus 26%. Phase 3 LIVERAGE ongoing.

What the studies show

Phase 2 in 293 patients: MASH improvement without worsening fibrosis in 83% at 4.8 mg versus 18% on placebo at 48 weeks; fibrosis improvement in 52% versus 26%. Phase 3 LIVERAGE ongoing.

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Sanyal AJ, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis.N Engl J Med, 2024; DOI 10.1056/NEJMoa2401755293 patients, 48 weeks.

In context

Survodutide is a once-weekly peptide that activates both the GLP-1 and glucagon receptors. In SYNCHRONIZE-1, a 725-person phase 3 trial published in June 2026, it produced 12–13% weight loss at 76 weeks against 5% on placebo, with gastrointestinal symptoms in up to 90% of participants. Its distinctive result is in the liver: a phase 2 trial resolved MASH without worsening fibrosis in 83% of patients at the top dose. It is not approved anywhere.

Survodutide is investigational. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Survodutide proven to help with liver disease?
Not yet settled. 1 phase 2 RCT; phase 3 running — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
Phase 2 in 293 patients: MASH improvement without worsening fibrosis in 83% at 4.8 mg versus 18% on placebo at 48 weeks; fibrosis improvement in 52% versus 26%. Phase 3 LIVERAGE ongoing.
Is Survodutide approved for this?
No. Survodutide is investigational; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Survodutide

Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →